United Therapeutics Corporation (UTHR)
Nasdaq: UTHR · Pharmaceutical Preparations · Silver Spring, MD · filing with the SEC since 1999
Grade7.3
◀ Past 7.7● Present 7.9▶ Future 6.1
Who owns United Therapeutics Corporation
As filed with the SECHolders of 5% or more
2
Rothblatt Martine A holds 5.3% of Common Stock, par value $.01 per share, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
16
report now, of 20 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Rothblatt Martine A
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $.01 per share
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Feb 5, 2025 · COMMON STOCK · reported falling below 5%
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · reported falling below 5%, from 5.7% in Feb 10, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What UTHR reports owning in othersstakes of 5% or more, and other ties
12 subsidiaries in 1 country, from the list filed with the 10-K filed Feb 25, 2026.
Insider tradesForm 4
2,897sales
1purchases
2,883sales on a scheduled plan
12people selling
$1.45Bsold, in dollars
$900,000bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 20 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Rothblatt Martine A | Chairperson & CEO | 2,176 | $972M | 2,176 | 1 | $900,000 |
| Edgemond James | CFO AND TREASURER | 365 | $193M | 365 | 0 | $0 |
| Benkowitz Michael | PRESIDENT AND COO | 125 | $159M | 125 | 0 | $0 |
| Mahon Paul A | EVP & GENERAL COUNSEL | 203 | $114M | 203 | 0 | $0 |
| Patusky Christopher | director | 4 | $3.4M | 2 | 0 | $0 |
| Sullivan Louis W | director | 2 | $3.0M | 0 | 0 | $0 |
| Thompson Tommy G | director | 5 | $2.5M | 0 | 0 | $0 |
| Kurzweil Ray | director | 1 | $2.4M | 0 | 0 | $0 |
| Causey Christopher | director | 5 | $2.3M | 5 | 0 | $0 |
| Mesa Nilda | director | 4 | $400,000 | 0 | 0 | $0 |
| Malcolm Jan | director | 9 | $400,000 | 9 | 0 | $0 |
| Olian Judy D. | director | 4 | $400,000 | 4 | 0 | $0 |